Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 25;13(2):417.
doi: 10.4081/oncol.2019.417. eCollection 2019 Jul 22.

Current promising treatment strategy for glioblastoma multiform: A review

Sanjib Bahadur  1 , Arvind Kumar Sahu  1 , Pragya Baghel  1 , Suman Saha  1
Affiliations

Current promising treatment strategy for glioblastoma multiform: A review

Sanjib Bahadur et al. Oncol Rev. .

Abstract

Glioblastoma multiform (GBM) is a heterogeneous group of primary neoplasm resistant to conventional therapies. Due to their infiltrative nature it not fully isolated by aggressive surgery, radiation and chemotherapy showing poor prognosis in glioma patients. Unfortunately, diagnosed patients die within 1.5-2 year treatment schedule. Currently temozolomide (TMZ) is the first choice for the prognosis of GBM patients. TMZ metabolites methyl triazen imidazol carboxamide form complex with alkyl guanine alkyl transferase (O6 MGMT- DNA repair protein) induced DNA damage following resistance properties of TMZ and inhibit the overall survival of the patients. Last few decades different TMZ conjugated strategy is developed to overcome the resistance and enhance the chemotherapy efficacy. The main aim of this review is to introduce the new promising pharmaceutical candidates that significantly influence the therapeutic response of the TMZ in context of targeted therapy of glioblastoma patients. It is hoped that this proposed strategy are highly effective to overcome the current resistance limitations of TMZ in GBM patients and enhance the survival rate of the patients.

Keywords: Glioblastoma; resistance; targeted therapy; temozolomide.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: the authors declare no potential conflicts of interest.

Figures

Figure 1.
Figure 1.
New molecules, with their structure, average weight and type, which have potential to enhance temozolomide response.
Figure 1.
Figure 1.
New molecules, with their structure, average weight and type, which have potential to enhance temozolomide response.
Figure 1.
Figure 1.
New molecules, with their structure, average weight and type, which have potential to enhance temozolomide response.
Figure 1.
Figure 1.
New molecules, with their structure, average weight and type, which have potential to enhance temozolomide response.
See this image and copyright information in PMC

References

    1. Simpson L, Galanis E. Recurrent glioblastoma multiforme : advances in treatment and promising drug candidates. Expert Rev Anticancer Ther 2006;6:1593-607. - PubMed
    1. Reardon D, Wen P. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist 2006;11:152-64. - PubMed
    1. Nakada M. The strategy for enhancing temozolomide against malignant glioma. Front Oncol 2012; 2:1-5. - PMC - PubMed
    1. Filho AZ. Autophagy inhibition improves the efficacy of curcumin/ temozolomide combination therapy in glioblastomas. Cancer Lett 2015;358:220-31. - PubMed
    1. Yuan Y. Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSCmtor signaling pathway. CNS Neurosci Ther 2012;00:1-11. - PMC - PubMed